Inicio - Neuroeconomix

» Why are burden of disease studies useful?

They allow us to unify premature death and disability into a single standard indicator that is disability-adjusted life years (DALYs)

The measurement of disease burden takes into account the sequelae of different diseases and their impact on people's quality of life

Know some key points of our last publication: "Burden of the disease attributable to obesity and overweight in Colombia"

See here
» Why is it useful to know the burden of obesity in Colombia?

Overweight and obesity are nutritional problems that have been increasing in recent years. Excess weight mainly affects the adult population and in higher proportion to women.

According to the 2015 update of the National Nutritional Health Survey (ENSIN), the prevalence of overweight and obesity has increased by 5.2 percentage points over 2010

Know some key points of our last publication: "Burden of the disease attributable to obesity and overweight in Colombia"

See here
» Results of the paper "Burden of Obesity Disease in Colombia"

Of the 59,347 deaths reported by DANE, 11,565 were estimated to be attributable to overweight and obesity

In this study, 997,371 DALYs were due to overweight and obesity, 45% of which corresponded to men. Of the total DALYs, 81% correspond to years lost to disability (YLD)

The conditions that contributed to the highest number of DALYs attributable to excess weight were: hypertension, type 2 diabetes mellitus, ischemic heart disease, and low back pain

Know some key points of our last publication: "Burden of the disease attributable to obesity and overweight in Colombia"

See here
» Implications of the results of the work "Burden of Obesity Disease in Colombia"

The findings of the study show the importance of interventions to prevent and treat overweight and obesity as they lead to multiple health problems that increase mortality and lead to disability

Considering that health resources are limited, interventions on the populations where the greatest benefit can be obtained in the long term, such as children and adolescents, should be prioritized

Know some key points of our last publication: "Burden of the disease attributable to obesity and overweight in Colombia"

See here

NEURO ECONOMIX

In the last 3 years we have successfully built more than 60 economic studies, 30 literature reviews and around 40 academic talks.

Testimonials from our clients prove the advantages and results of working with a company with technical, strategic and multidisciplinary solidity.

We are a consultant that develops solutions in access, sustainability and results to all actors of the health system, through high quality technical and commercial inputs.

Adoption and adaptation of CPG and clinical pathways

Conferences and workshops- NexTalks

Real World Studies

Systematic reviews

Economic studies

Burden of disease studies

Processing of forms for nominations for the Health Benefits Plan

Evidence-based Recommendations

Online solutions

Processing Invima forms

Download the Brochure

Our work is strategically planned, according to your needs, and built with the highest quality, you are in the hands of one of the leading teams in Colombia and Latin America, with a large number of publications in indexed journals.

Diego Rosselli

A Colombian neurologist, trained at the London Institute of Psychiatry, and started his academic career as a neuroscience teacher. After obtaining his Master’s degree in Education in Harvard in 1993, he joined the Colombian Ministry of Health as Director for Scientific and Technological Development, in charge of performing health technology assessments.

OUR BLOG

SUBSCRIBE TO OUR BLOG

BOARD OF CONSULTANTS

Javier Ricardo Garzón Herazo M.D. Esp.

Infectólogo

Daniel Fernández Ávila M.D. MSc. Ph.D.(c)

Reumatólogo

Jheremy Enrique Reyes Castellanos M.D. Esp.

Hemato-Oncólogo

Maria Fernanda Delgado Morales M.D.

Oftalmóloga. Esp. en Glaucoma

Andrés Garzón Forero M.D. Esp.

Internista

“Al tener la oportunidad de trabajar hace varios años con el Dr. Rosselli y su equipo de investigación, he encontrado la solución a las necesidades de investigación, proyectos de farmacoeconomía y análisis de data, con un muy alto nivel de calidad, compromiso y entrega”

Ana María Serrato
Country Manager
Bioverativ

“La interacción con el equipo es muy positiva, lo que facilita el cumplimiento tanto de los objetivos como de los tiempos definidos. Por las anteriores razones, recomiendo ampliamente a tan buen equipo”.

Ludy Parada MSc
Gerente de Acceso- área cardiopulmonar
Bayer

“Este grupo de evaluación de tecnologías en salud, se caracteriza por su rigurosidad metodológica para abordar aspectos relacionados con la investigación de resultados en salud y la farmacoeconomía. Sus trabajos han tenido gran impacto en congresos médicos y de evaluación de tecnologías en salud, particularmente en ISPOR”.

“El éxito de este grupo consultor radica en mezclar la experiencia con una estrategia de comunicación efectiva, permitiendo que los resultados sean compresibles para los distintos actores del sistema de salud colombiano. Por esta razón me siento a gusto y complacido de trabajar con ellos”

Victor Prieto
HEOR Manager
Pfizer Colombia

“Este es un grupo de investigación comprometido con los proyectos, con una alta calidad técnica de los mismos y con la disposición de presentar esta información donde se requiriera para obtener un mejor entendimiento de los resultados. De presentarse la oportunidad trabajaría de nuevo con este grupo debido a su cumplimiento y excelente calidad de su trabajo”.

Nicolás Vargas Zea MSc. MBA.
Market Access and Pricing Director
Colombia Merck Serono | Global

“He tenido la oportunidad de trabajar con este excelente equipo de trabajo. No solamente tienen un gran conocimiento técnico si no que son excelentes seres humanos, lo que ha hecho que las dinámicas de trabajo y discusiones en torno a los constantes cambios del sistema de salud se convierta en un aprendizaje continuo. Son flexibles y se ve que a cada proyecto le ponen su mayor interés. Es por esto que recomendaría ampliamente trabajar con este gran equipo”.

Felice Leonardi Reyes
Pharmacoeconomics & Strategic Alliances Manager
Eli Lilly Colombia

“Neuroeconomix crea soluciones a la medida, con rigurosidad científica y altos estándares de calidad. Realizar un proyecto con ellos es vivenciar el trabajo en equipo, la ética, el cumplimiento, y la posibilidad de generar evidencia de gran impacto para la toma de decisiones en salud”.

Marcela Pérez
Gerente de Economía de la Salud
Amgen